Testing

Christopher Klein, M.D., and Erik Thorland, Ph.D., give an overview of the new hereditary epilepsy panels available through Mayo Clinic Laboratories. They discuss the Mayo Clinic testing approach, interpretation and results, and custom gene ordering.

By alyssafrank • December 4, 2018

Visit us at booth #2927 at the American Society of Hematology in San Diego from Saturday, December 1 through Monday, December 3 to discuss how our state-of-the-art hematology testing can integrate with your practice.

By mayocliniclabs • November 29, 2018

David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests.

By alyssafrank • November 28, 2018

In October 2018, Mayo Medical Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.

By alyssafrank • November 13, 2018

Robert Jenkins, M.D., Ph.D., a pathologist and cancer geneticist at Mayo Clinic, provides an overview of the new neuro-oncology expanded gene panel and chromosomal microarray testing available through Mayo Medical Laboratories. He discusses which types of patients should be tested, how these tests improves upon previous methods, and what clinical action can be taken from the results of this testing.

By alyssafrank • November 12, 2018

Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.

By alyssafrank • October 25, 2018

Chromium and cobalt blood tests are used to monitor exposure to these elements. Both of these elements are naturally occurring and widely distributed in the environment. Previously, serum samples were collected and used to monitor patients with metal-on-metal implants, but serum can easily be contaminated during the harvesting and separation of the serum from the cellular blood components causing incorrect results. By using the new EDTA anticoagulated whole-blood test, which is collected in a trace element tube instead of using serum, the risk of contamination is significantly reduced.

By alyssafrank • October 19, 2018

In September 2018, Mayo Medical Laboratories announced two new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By alyssafrank • October 11, 2018

In August 2018, Mayo Medical Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.

By alyssafrank • September 20, 2018

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant vascular dysplasia characterized by the presence of arteriovenous malformations of the skin, mucosa, and viscera. Linnea Baudhuin, Ph.D., FACMG, Co-Director of the Personalized Genomics Laboratory at Mayo Clinic, provides an overview of the new familial HHT gene panel available through Mayo Medical Laboratories. She discusses which types of patients should be tested, how this approach improves upon previous methods, and what clinical action can be taken from the results of this test.

By alyssafrank • September 19, 2018

At Mayo Clinic, we offer a comprehensive approach to testing that focuses on the best outcomes for the patient. Our testing method combines molecular and cytogenetic analysis (in addition to a standard morphological and histological assessment) to provide a clear picture of the diagnosis, prognosis, and treatment options. This approach maximizes the amount of information available, allowing for a tailored treatment plan.

By mayocliniclabs • September 17, 2018

The following list of updates were posted to MayoMedicalLaboratories.com during the month of August 2018: […]

By Erika Fetterman • September 14, 2018

Many patients may have flare-ups of their disease, or they may stop responding to treatment. In these situations, the clinician may choose to increase the dose administered or recommend more frequent injections. One cause of decreased response to treatment is the appearance of anti-drug antibodies or “immunogenicity.”

By mayocliniclabs • September 7, 2018